Collecting real-world data on the management of metastatic colorectal cancer (mCRC)
The purpose of PROMETCO is to provide real-world data on overall survival, treatment patterns, associated effectiveness and safety, and impact on patients with mCRC throughout the continuum of care1
CRC is a major public health burden2,3
- 1.85 million new cases in 2018
- 881,000 deaths in 2018
- <10% survival rate in patients with stage IV CRC
Latest news
FatCamera/E+ © Getty images
Published November 8, 2022
We are pleased to announce that the PROMETCO study recruitment period ended on October 31, 2022. We ended the recruitment period with a total of 738 patients enrolled in PROMETCO.
Final recruitment numbers
18
Participating
countries
98
Investigational sites
96 recruiting
2 non-recruiting
738
Patients enrolled
Number of patients per country as of the end of the recruitment period on October 31, 2022
ARG: Argentina, AUT: Austria, BEL: Belgium, CHE: Switzerland, CZE: Czech Republic, DEU: Germany, ESP: Spain, FRA: France, GRE: Greece, HRV: Croatia, HUN: Hungary, IRL: Ireland, ITA: Italy, NLD: Netherlands, PRT: Portugal, SVN: Slovenia, SWE: Sweden, UK: United Kingdom
Why PROMETCO
PROMETCO rationale
Advances in treatment of mCRC in the past 15 years have improved patient survival to ~30 months based on data from RCTs4
Data from prospective real-world studies are lacking
PROMETCO aims to address this gap
PROMETCO study objectives
Study objectives are to describe the following for mCRC patients in a real-world setting:
Overall survival
Treatment patterns for mCRC throughout the continuum of care
Effectiveness/safety of treatments in a real-world setting
Reasons for therapy discontinuations and choice of subsequent treatment
Adherence to national and ESMO guidelines
Healthcare resource utilization
Patient-reported outcomes
